Anteris Technologies (ASX:AVR) - Chief Executive, Wayne Paterson
Chief Executive, Wayne Paterson
Source: Anteris Technologies (Twitter)
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Anteris Technology (AVR) has demonstrated what it calls “superior” calcification attributes of its ADAPT treated tissue, when compared with tissues in competitor valves
  • The study used a well-established rat model to determine whether different anti-calcification methods were likely to have clinical relevance
  • Four samples — including ADAPT, AOA Porcine, AOA Bovine and the control GA-treated bovine pericardium —were planted subcutaneously in 48 rats
  • Results from the study showed that the ADAPT tissue technology — used in the DurAVR 3D single-piece aortic valve —had roughly 38 per cent less calcium concentration compared with the Medtronic AOA porcine arm
  • Anteris’ product also recorded 26 per cent less calcium in the AOA bovine arm
  • AVR is planning for a further head-to-head study comparing ADAPT with both Medtronic’s AOA and Edwards Life Science’s next generation TAVR tissue treatment, Resilia
  • Anteris Technology shares are down 7.52 per cent, trading at 11.93 cents each

Anteris Technology (AVR) has demonstrated what it calls the “superior” calcification attributes of its ADAPT treated tissue, compared with tissues in competitor valves.

The structural heart company is focussed on developing next generation technologies that help healthcare professionals create life-changing outcomes for patients.

For the study, Anteris used a well-established rat model to determine whether different anti-calcification methods were likely to have clinical relevance.

This involved subcutaneously planting four samples — including ADAPT, AOA Porcine, AOA Bovine and the control GA-treated bovine pericardium — in 48 rats.

The animals were subsequently sacrificed at four and eight months after implantation, and their tissues analysed both histologically and for calcium-per-tissue weight.

The results showed that Anteris’ ADAPT tissue technology — used in the DurAVR 3D single-piece aortic valve —had roughly 38 per cent less calcium concentration compared with the Medtronic AOA porcine arm.

Anteris’ product also recorded 26 per cent less calcium in the AOA Bovine arm.

Additionally, the geometric mean (GM) calcium content for ADAPT was significantly less than the geometric mean for AOA Bovine and significantly less for AOA Porcine.

For calcium, the geometric mean for ADAPT was 26 per cent less than the GM for AOA Bovine, and 38 per cent less than the GM for AOA Porcine.

Dr Philip McCloud, a biostatistician from McCloud Consulting Group, performed an independent review of the data.

“The GM ratios demonstrated clear separation between the 95 per cent calcium and 1.0, thus confirming the highly significant reduction of calcium for the ADAPT arm compared to the AOA Bovine arm, and AOA Porcine arm,” Dr McCloud said.

The results correlate with existing clinical data and data from the prior head-to-head study, which used a similar protocol to produce significant differentials between ADAPT tissue and Edwards Life Sciences’ Thermafix tissue at the eight to 12-month mark.

“These findings clearly demonstrated the superior performance of the ADAPT tissue engineered process as an anti-calcification technology against some of the top competitors in the marketplace,” Anteris Technology CEO Wayne Peterson commented.

“It further supports previous human studies and clinical experience demonstrating ADAPT has a clinical relevant profile in terms of resisting calcification,” Wayne continued.

Based on these results, Anteris is planning a further head-to-head study comparing the ADAPT treatment with both Medtronic’s AOA and Edwards Life Science’s next generation TAVR tissue treatment Resilia.

Anteris Technology shares are down 7.52 per cent, trading at 11.93 cents at 3:16 pm AEDT.

AVR by the numbers
More From The Market Herald
Hexima (ASX:HXL) - CEO & Managing Director, Michael Aldridge

" Hexima’s (ASX:HXL) shares plummet on inconclusive clinical results for pezadeftide

Hexima's (ASX:HXL) shares have taken a hit today after phase two preliminary results for its pezadeftide…
The Market Herald Video

" PainChek (ASX:PCK) taps investors for $4.5m to push commercial rollout

PainChek (ASX:PCK) is looking to raise $4.59 million through an entitlement offer and placement to accelerate…
Bod Australia (ASX:BOD) - CEO, Jo Patterson

" Bod Australia (ASX:BOD) to launch new medicinal cannabis product in July

Bod Australia (ASX:BDA) will launch a new medicinal cannabis product under its existing MediCabilis brand to…
Telix Pharmaceuticals (ASX:TLX) - CEO, Dr Christian Behrenbruch

" Telix Pharmaceuticals (ASX:TLX) signs licence and distribution agreement for Illuccix

Telix Pharmaceuticals (ASX:TLX) signs a licence and distribution agreement with Isologic.